Allergan said it would support a shareholder proposal that will require “an independent board chair to be phased in during the next leadership transition.”
The announcement “reflects our board’s ongoing commitment to active board refreshment and governance best practices, as well as continuous engagement with our shareholders,” said Chris Coughlin, the lead independent director of Allergan’s board.
No further details about the proposal were disclosed.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
